Today's Date: March 18, 2024
Spire Global to Enhance AI-Driven Weather Prediction in Collaboration with NVIDIA   •   EarthX to Feature Benji Backer, Author of "The Conservative Environmentalist," at Upcoming Congress of Conferences   •   Hyundai Showcases Refined-Rugged SUV Experience in New Asian American Campaign for the All-New Santa Fe   •   Cadence and NVIDIA Unveil Groundbreaking Generative AI and Accelerated Compute-Driven Innovations   •   New ASEAN Energy and ACTUAL Sign Cooperation Agreement to Develop Net-Zero Plan for the New $5B USD Pengerang Energy Complex   •   SBS TO RECEIVE MULTIMILLION DOLLAR SETTLEMENT FROM VOZ MEDIA   •   Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant   •   Carlisle Companies to Acquire MTL Holdings, a Leader in Edge Metal and Non-Insulated Architectural Wall Systems   •   Using Banuba SDKs Gives Businesses an Advantage in the Case of TikTok Ban   •   Smarter AI for All: Lenovo Unveils Hybrid AI Solutions that Deliver the Power of Tailored Generative AI to Every Enterprise and   •   Consumers Energy Expands MI Clean Air, Allowing Customers to Offset Carbon Emissions   •   EverWind Fuels Praises Historic Canada-Germany Agreement to Sell Canadian Green Hydrogen   •   College of Saint Mary Selects YuJa Enterprise Video Platform as Campuswide Media Creation and Distribution Solution   •   UL Solutions and SINAI Technologies Join Forces to Help Customers Enhance Decarbonization and ESG Performance and Reporting   •   NAREB PREPARES MEMBERS FOR MAJOR CHANGES TO HOME SALES AGENT COMMISSIONS AFTER LAWSUIT SETTLEMENT   •   Statement by Minister Qualtrough on the Closing of the 2024 Arctic Winter Games in the Mat-Su Valley, Alaska   •   UNLOCK SPRING LEARNING: THE TOY ASSOCIATION™'S NEW STEAM ACCREDITED TOY LIST OFFERS 25 ENGAGING TOYS FOR KIDS   •   Mbanq and The Financial Policy Council to Host: “Business Banking Battles – Big Value in the Face of Bank Industry T   •   Mitsubishi Electric Named to CDP Supplier Engagement Leader   •   TM Associates Announces Grand Opening of Luxury Affordable Apartment Community in DC, MDXL Flats Apartments
Bookmark and Share

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. & BOSTON , February 01 /Businesswire/ - Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January 31, 2023.

Six individuals hired by Adicet in January 2023 received, in the aggregate, non-qualified stock options to purchase 72,800 shares of Adicet’s common stock with an exercise price of $9.15 per share, the closing price of Adicet’s common stock as reported by Nasdaq on January 31, 2023. One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of each recipient’s start date and thereafter the remaining three-fourths of the shares underlying each employee’s option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient’s start date, in each case, subject to each such employee’s continued employment with Adicet on such vesting dates.

All of the above-described awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.


STORY TAGS: Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Share Issue, California, Massachusetts, United States, North America,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News